|Creating the next generation of cancer treatments
BOARD OF DIRECTORS
Arie S. Belldegrun, MD - Chairman of the Board of Directors
Dr. Belldegrun currently serves as Chairman of the Board of Directors of the Company. He is also Chairman and Partner at Two River, Executive Chairman and founder of Kite Pharma, Inc., and a Director of Nile Therapeutics, Inc. (OTCBB: NLTX).
Dr. Belldegrun is Professor of Urology, holds the Roy and Carol Doumani Chair in Urologic Oncology, and is Director of the UCLA Institute of Urologic Oncology at the David Geffen School of Medicine at UCLA. Dr. Belldegrun has been closely involved with the founding, development and sale of several private and public biopharmaceutical companies. In 1996, Dr. Belldegrun founded Agensys, Inc. and served as its founding Chairman of the board of directors. In December 2007, Agensys was acquired by Astellas Pharma, Inc., in a deal valued at $537 million. Dr. Belldegrun was also the founding vice-chairman of the board of directors and chairman of the scientific advisory board of Cougar Biotechnology, Inc. that was acquired by Johnson & Johnson in 2009 in a $970 million transaction. In April 2011, the FDA approved abiraterone acetate (Zytiga™), Cougar's lead product, for late-stage prostate cancer.
Dr. Belldegrun completed his M.D. at the Hebrew University Hadassah Medical School in Jerusalem, his post graduate fellowship at the Weizmann Institute of Science and his residency in Urological Surgery at Harvard Medical School. Prior to UCLA, Dr. Belldegrun was at the National Cancer Institute/NIH as a research fellow in surgical oncology and immunotherapy under Dr. Steven A. Rosenberg. He has authored more than 400 scientific and medical papers related to urological cancers, immunotherapy, gene therapy, and cancer vaccines. He is certified by the American Board of Urology, and is a Fellow of the American College of Surgeons and the American Association of Genitourinary Surgeons (AAGUS).
Alexander Zukiwski, M.D.
Chief Executive Officer and Chief Medical Officer
Dr. Zukiwski is responsible for leading the clinical development and regulatory affairs teams supporting Arno's current and future pipeline of innovative cancer therapies. He has more than 15 years of experience in global oncology drug development and has supported the clinical evaluation and registration of many successful therapeutic agents, including Taxotere®, Xeloda®, Procrit®/Eprex®, Velcade®, Yondelis® and Doxil®. Dr. Zukiwski was most recently Executive Vice President, Clinical Research, and Chief Medical Officer at MedImmune, Inc. where the organization he led was responsible for developing and implementing MedImmune's clinical research, medical affairs and safety strategies. Prior to joining MedImmune, Dr. Zukiwski held medical affairs and clinical development positions of increasing responsibility at Johnson & Johnson Pharmaceutical Research & Development, LLC (JJPRD), Centocor and Ortho Biotech, including serving as therapeutic area head for oncology and acting head of oncology research and development. Before joining Johnson & Johnson, Dr. Zukiwski held clinical oncology positions at Hoffmann-LaRoche, Glaxo Wellcome and Rhone-Poulenc Rorer. He received a bachelor's degree in pharmacy from the University of Alberta and a Doctor of Medicine degree from the University of Calgary and conducted post-graduate training at St. Thomas Hospital Medical Center in Akron, Ohio and the University of Texas, M.D. Anderson Cancer Center.
William F. Hamilton - Director
Dr. Hamilton has served on the University of Pennsylvania faculty since 1967, and is the Landau Professor of Management and Technology, and Director of the Jerome Fisher Program in Management and Technology at The Wharton School and the School of Engineering and Applied Science. Dr. Hamilton also serves on the boards of directors of Yaupon Therapeutics, Inc., a privately held specialty pharmaceutical company that develops small molecule pharmaceuticals licensed from academic laboratories, and Neuro Diagnostic Devices Inc., a privately held development-stage medical-device company, and was previously a director of Avid Radiopharmaceuticals, Inc., a clinical-stage molecular-imaging company which was acquired by Eli Lilly in 2010. Dr. Hamilton received his B.S. and M.S. in chemical engineering and his MBA from the University of Pennsylvania, and his Ph.D. in applied economics from the London School of Economics.
Tomer Kariv - Director
Mr. Kariv is the co-founder and Chief Executive Officer of Pontifax, a group of Israeli based life sciences venture funds focusing on investments in development stage bio-pharmaceutical and med-tech technologies. Mr. Kariv serves as an active board member of many of the funds' portfolio companies, assuming a special responsibility for strategic planning. Among others, Mr. Kariv serves as the Chairman of Check-Cap Ltd and is a board member of Macrocure Ltd, Arno Therapeutics Inc. and Aposense Ltd. During the 10 years prior to establishing Pontifax, Mr. Kariv played a key role in investing, managing and nurturing technology driven companies and startups and has held senior management positions at top Israeli financial institutions. Mr. Kariv practiced law with Sullivan & Cromwell, a leading corporate law firm in New York, and holds a B.A. in Economics from Harvard University and a J.D. from Harvard Law School.
Yacov Reizman - Director
Mr. Reizman has been the Chairman and Chief Executive Officer of FCC Ltd., a private investment company that he founded in 1987. Over the past decade FCC has invested directly in over 50 publicly traded and privately held companies in a diverse range of industries including: infrastructure; shipping; healthcare; and financial services. FCC also specializes in corporate finance and structured investments. Mr. Reizman was also co-founder and co-CEO of Azimuth Ltd., which traded on the TASE. Previously Mr. Reizman served in the Israeli Air Force (IAF) as a fighter pilot (Major) and led large-scale high-tech projects for the IAF, including joint projects with Israeli and U.S. defense industries. Mr. Reizman holds a B.A. in economics and in psychology from Tel Aviv University.
Steven Ruchefsky - Director
Since 2010, Mr. Ruchefsky has been President of Commercial Street Capital LLC, a private investment company and significant stockholder in Arno Therapeutics Inc. He also serves as a private investment manager for S. Donald Sussman, the founder and CEO of a multi-billion dollar hedge fund. During his tenure with Mr. Sussman, Mr. Ruchefsky was responsible for the initial funding of Cougar Biotechnology Inc., later acquired by Johnson & Johnson, and Ziopharm Oncology Inc. (ZIOP: NASDAQ). Mr. Ruchefsky began his career at the New York City law firm, Morrison Cohen, where he became a partner, member of management and chair of a specialized litigation group. Upon leaving Morrison Cohen and prior to his current employment, Mr. Ruchefsky was a principal of an early-stage venture capital operation. Mr. Ruchefsky currently sits on the boards of several public and private companies, including Kite Pharma Inc (KITE: NASDAQ), MD Solar Sciences and Energy Pioneer Solutions. Mr. Ruchefsky is a graduate of The George Washington University Law School.
David M. Tanen - Director and Secretary
David M. Tanen - Director and Corporate Secretary. Mr. Tanen, a co-founder of Arno, currently serves as Secretary of Arno and a member of its Board of Directors. In September 2004, he co-founded Two River and currently serves as Vice President and Director of Two River's managing member, Two River Group Management, LLC. He is also an officer of the managing member of Two River Consulting, LLC, an organization that provides management, consulting and operational services for development stage biotechnology companies. Mr. Tanen also serves as Senior Managing Director of Riverbank Capital Securities, Inc, a FINRA member broker dealer that specializes in conducting private placement financings for public and private development-stage biotechnology companies. Prior to founding Two River, from October 1996 to September 2004, he was a Director of Paramount BioCapital Investments, LLC.
Mr. Tanen currently serves as an officer and director of several privately held biotechnology companies. He received his B.A. from The George Washington University and his J.D. from Fordham University School of Law.